Swedish Growth Companies With High Insider Ownership To Watch In May 2024

As global markets show signs of stabilization with moderated inflation and interest rate adjustments, Sweden's economic landscape presents a unique opportunity for investors interested in growth companies with high insider ownership. Such companies often benefit from aligned interests between management and shareholders, fostering robust governance and potentially enhancing long-term value creation in these evolving market conditions.

Top 10 Growth Companies With High Insider Ownership In Sweden

Name	Insider Ownership	Earnings Growth
CTT Systems (OM:CTT)	16.9%	21.6%
Spago Nanomedical (OM:SPAGO)	16.1%	52.1%
BioArctic (OM:BIOA B)	35.1%	63%
Calliditas Therapeutics (OM:CALTX)	11.6%	49.9%
Sileon (OM:SILEON)	33.3%	109.3%
InCoax Networks (OM:INCOAX)	18.9%	104.9%
KebNi (OM:KEBNI B)	37.8%	90.4%
Egetis Therapeutics (OM:EGTX)	17.6%	98.2%
Yubico (OM:YUBICO)	37.5%	43%
SaveLend Group (OM:YIELD)	24.8%	106.8%

Click here to see the full list of 84 stocks from our Fast Growing Swedish Companies With High Insider Ownership screener.

Let's review some notable picks from our screened stocks.

BioArctic (OM:BIOA B)

Simply Wall St Growth Rating: ★★★★★★

Overview: BioArctic AB (ticker: OM:BIOA B) is a Swedish biopharmaceutical company focused on developing treatments for central nervous system disorders, with a market capitalization of approximately SEK 19.70 billion.

Operations: The company's revenue is generated from the development of biological drugs targeting central nervous system disorders.

Insider Ownership: 35.1%

Return On Equity Forecast: 32% (2027 estimate)

BioArctic, a Swedish biopharmaceutical company, has recently faced a significant earnings decline with Q1 sales dropping to SEK 29.64 million from SEK 393.43 million the previous year and shifting from a net income to a net loss of SEK 57.56 million. Despite these challenges, the company is poised for recovery with expected high revenue growth of 48.1% per year and anticipated profitability within three years. The stock is currently undervalued, trading at 66.5% below its estimated fair value, and analysts forecast a substantial price increase of 64.2%. Additionally, BioArctic continues to innovate in Alzheimer's treatment through strategic alliances like the recent agreement with Eisai on BAN2802 using their BrainTransporter™ technology.

• Click to explore a detailed breakdown of our findings in BioArctic's earnings growth report.
• Our valuation report here indicates BioArctic may be undervalued.

Fortnox (OM:FNOX)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Fortnox AB operates in providing financial and administrative software solutions tailored for small to medium-sized businesses and accounting firms, with a market capitalization of approximately SEK 43.11 billion.

Operations: The company generates revenue through various segments, including Core Products at SEK 698 million, Entrepreneurship at SEK 356 million, The Agency at SEK 327 million, and Marketplaces at SEK 150 million.

Insider Ownership: 21%

Return On Equity Forecast: 33% (2027 estimate)

Fortnox, a Swedish software company, reported strong financial performance with Q1 sales increasing to SEK 467 million from SEK 370 million year-over-year. Earnings also rose significantly, with net income reaching SEK 149 million. Despite limited insider buying recently, Fortnox shows robust growth prospects with earnings expected to grow by 21.11% per year and revenue forecasted at an annual increase of 19.6%, outpacing the Swedish market average. The company's return on equity is projected to be high at 33.2% in three years.

• Click here to discover the nuances of Fortnox with our detailed analytical future growth report.
• Our expertly prepared valuation report Fortnox implies its share price may be too high.

AB Sagax (OM:SAGA A)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: AB Sagax (publ) is a property company with operations across Sweden, Finland, France, Benelux, Spain, Germany, and other European countries, boasting a market capitalization of approximately SEK 103.47 billion.

Operations: The company generates its revenue primarily from real estate rentals, amounting to SEK 4.47 billion.

Insider Ownership: 28.3%

Return On Equity Forecast: N/A (2027 estimate)

AB Sagax, a Swedish real estate company, has demonstrated strong financial recovery with first quarter sales rising to SEK 1.19 billion from SEK 1.01 billion year-over-year and net income significantly improving to SEK 1.08 billion from a net loss of SEK 267 million. Despite some shareholder dilution over the past year, earnings are expected to grow by approximately 33.75% annually over the next three years, outperforming the Swedish market's forecasted growth rate of 14.3%. However, its debt is poorly covered by operating cash flow, indicating potential financial stress.

• Delve into the full analysis future growth report here for a deeper understanding of AB Sagax.
• Our valuation report unveils the possibility AB Sagax's shares may be trading at a premium.

Turning Ideas Into Actions

• Unlock our comprehensive list of 84 Fast Growing Swedish Companies With High Insider Ownership by clicking here.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com